Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SULFINPYRAZONE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 991 records · Page 55Linked to original sources
PubMed1979

Studies on kinetics of anturan excretion in man.

The kinetics of anturan excretion was studied. Experiments were carried out on ten healthy volunteers. The drug was given orally once applying three different doses: 100, 200, 400 mg. The contents of the drug in urine were determined by means of the modified method worked out by Wallace. It was found about 42 per cent of the dose was excreted with urine in an unchanged form. The process of anturan excretion may be described according to the one-compartment open kinetic model. The half-life of excretion is 3.5 hours, the excretion constant is 0.20. The formula showing the course of anturan excretion in time has been given. Five examples of the quantitative exposure test have been proposed; they allow the calculation of the absorbed drug dose and thus the degree of poisoning. The test can be also helpful in controlled therapy.

Female↗
PubMed1979

The effect of agents which modify platelet behaviour and of magnesium ions on thrombus formation in vivo.

The ability of potential anti-thrombotic agents to modify platelet-thrombus formation in injured cerebral arteries in the rabbit was tested. Low doses of heparin were without effect, while higher doses produced variable suppression of white body formation but at the expense of bleeding. Aspirin did not inhibit white body formation but another non-steroid anti-inflammatory agent, flurbiprofen was able to do so, as was the anti-gout agent, sulphinpyrazone. Magnesium salts both topically and parenterally, suppressed thrombus formation and increased the concentration of ADP which was required to initiate thrombus production at minor injury sites.

Animals↗
PubMed1971

[Gout].

Explore the source record for details and available documents.

Adult↗
PubMed1979

Reduction of dialyzer fibrin deposition with sulphinpyrazone.

To determine whether sulphinpyrazone reduces thrombus formation within artificial kidneys, dialyzer 125I-fibrinogen and platelet and fibrinogen levels during dialysis were compared during a non-treatment control period and while patients were receiving sulphinpyrazone. Mean fibrin deposition within the dialyzers, measured as gram X 10(-3) of clottable fibrinogen, was significantly less during sulphinpyrazone treatment (2.5) than during the control period (5.3). Arterial blood platelet counts and plasma fibrinogen levels during dialysis were higher on treatment despite similar predialysis values during control and treatment periods. The results indicate that sulphinpyrazone reduces fibrin formation within artificial kidneys and, since the reduction in deposition of fibrin alone is insufficient to explain the higher plasma fibrinogen levels during treatment with sulphinpyrazone, suggests that this therapy reduces fibrinogen consumption within the patient during hemodialysis.

Blood Platelets↗